Amyris (AMRS) Given a $11.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $11.00 price target on Amyris (NASDAQ:AMRS) in a research note published on Tuesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Amyris from a hold rating to a sell rating in a research report on Tuesday, October 9th. BidaskClub raised shares of Amyris from a hold rating to a buy rating in a research report on Wednesday, August 15th. Finally, B. Riley set a $10.00 price objective on shares of Amyris and gave the company a buy rating in a research report on Monday, September 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Amyris currently has a consensus rating of Buy and an average target price of $8.83.

Shares of AMRS stock opened at $4.34 on Tuesday. Amyris has a one year low of $3.19 and a one year high of $9.28.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($1.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.96). The company had revenue of $14.90 million for the quarter, compared to the consensus estimate of $46.72 million. During the same quarter last year, the business earned ($0.81) earnings per share. The business’s revenue was down 38.4% compared to the same quarter last year. As a group, equities analysts expect that Amyris will post -1.34 earnings per share for the current year.

In other news, insider John Melo sold 5,195 shares of the firm’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $7.50, for a total transaction of $38,962.50. Following the sale, the insider now owns 743,713 shares of the company’s stock, valued at approximately $5,577,847.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Kathleen Valiasek purchased 23,000 shares of the company’s stock in a transaction dated Tuesday, November 27th. The shares were bought at an average cost of $4.37 per share, for a total transaction of $100,510.00. Following the acquisition, the chief financial officer now owns 251,630 shares in the company, valued at $1,099,623.10. The disclosure for this purchase can be found here. Company insiders own 21.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vivo Capital LLC boosted its holdings in shares of Amyris by 97.2% during the 3rd quarter. Vivo Capital LLC now owns 5,575,118 shares of the biotechnology company’s stock valued at $44,266,000 after acquiring an additional 2,748,407 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Amyris by 32.8% during the 3rd quarter. BlackRock Inc. now owns 2,277,432 shares of the biotechnology company’s stock valued at $18,082,000 after acquiring an additional 562,877 shares during the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of Amyris during the 3rd quarter valued at about $7,828,000. AWM Investment Company Inc. purchased a new stake in shares of Amyris during the 3rd quarter valued at about $5,876,000. Finally, Allianz Asset Management GmbH boosted its holdings in shares of Amyris by 56.0% during the 3rd quarter. Allianz Asset Management GmbH now owns 643,630 shares of the biotechnology company’s stock valued at $5,110,000 after acquiring an additional 231,145 shares during the last quarter. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

About Amyris

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Further Reading: How accurate is the Rule of 72?

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply